167.60
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RGEN Giù?
Forum
Previsione
Precedente Chiudi:
$169.61
Aprire:
$167.26
Volume 24 ore:
806.06K
Relative Volume:
0.71
Capitalizzazione di mercato:
$9.46B
Reddito:
$763.34M
Utile/perdita netta:
$51.40M
Rapporto P/E:
184.50
EPS:
0.9084
Flusso di cassa netto:
$104.46M
1 W Prestazione:
-4.92%
1M Prestazione:
+11.90%
6M Prestazione:
+33.18%
1 anno Prestazione:
+38.99%
Repligen Corp Stock (RGEN) Company Profile
Nome
Repligen Corp
Settore
Industria
Telefono
(781) 449-9560
Indirizzo
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, RMD, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
RGEN
Repligen Corp
|
167.60 | 10.17B | 763.34M | 51.40M | 104.46M | 0.9084 |
|
ISRG
Intuitive Surgical Inc
|
366.70 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
|
BDX
Becton Dickinson Co
|
184.74 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ALC
Alcon Inc
|
70.50 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
RMD
Resmed Inc
|
228.35 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
|
MDLN
Medline Inc
|
36.59 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-01 | Iniziato | HSBC Securities | Buy |
| 2025-09-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-07-22 | Ripresa | Stephens | Overweight |
| 2025-06-24 | Iniziato | Barclays | Overweight |
| 2025-04-29 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | Iniziato | Evercore ISI | In-line |
| 2025-02-10 | Iniziato | TD Cowen | Buy |
| 2024-12-17 | Iniziato | Canaccord Genuity | Hold |
| 2024-11-14 | Iniziato | Wolfe Research | Peer Perform |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-26 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-06-18 | Iniziato | Guggenheim | Neutral |
| 2023-12-04 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-07-20 | Iniziato | Wells Fargo | Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-03-28 | Iniziato | The Benchmark Company | Buy |
| 2022-12-14 | Iniziato | Deutsche Bank | Hold |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | Iniziato | UBS | Buy |
| 2021-10-14 | Iniziato | Exane BNP Paribas | Outperform |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-11-01 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | Iniziato | SVB Leerink | Outperform |
| 2019-08-28 | Reiterato | First Analysis Sec | Outperform |
| 2019-08-23 | Ripresa | Stephens | Overweight |
| 2019-07-22 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | Aggiornamento | CL King | Neutral → Buy |
| 2018-11-12 | Downgrade | CL King | Buy → Neutral |
| 2018-09-26 | Iniziato | H.C. Wainwright | Neutral |
| 2017-12-08 | Iniziato | Citigroup | Buy |
| 2017-12-05 | Iniziato | JP Morgan | Overweight |
| 2017-11-13 | Iniziato | CL King | Buy |
| 2017-10-02 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | Iniziato | William Blair | Outperform |
| 2017-02-13 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
Mostra tutto
Repligen Corp Borsa (RGEN) Ultime notizie
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen (NASDAQ: RGEN) CEO trades shares at $180 under 10b5-1 plan - Stock Titan
LVIP Baron Growth Opportunities Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen rises as investors continue to digest raised 2026 guidance and the BioLife deal - Quiver Quantitative
Repligen (NASDAQ: RGEN) plan covers 5,426-share sale after option exercise - Stock Titan
Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com - Investing.com South Africa
Repligen Corporation stock hits 52-week high at 176.52 USD - Investing.com
Oppenheimer Asset Management Inc. Purchases New Position in Repligen Corporation $RGEN - MarketBeat
Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A - Stock Titan
Repligen Corporation (RGEN) Stock Forecasts - Yahoo! Finance Canada
Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN - MarketBeat
Assenagon Asset Management S.A. Buys New Shares in Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026 - Yahoo Finance
Repligen Corp (RGEN) Stock News Today - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
The Manufacturers Life Insurance Company Decreases Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late to Buy Repligen Corp (RGEN) After 5.8% Rally? GF Value Says Undervalued - GuruFocus
Moody National Bank Trust Division Makes New Investment in Repligen Corporation $RGEN - MarketBeat
California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN - MarketBeat
Repligen Submits Form 425 Detailing Proposed Acquisition of BioLife Solutions - Kalkine Media
Repligen Corp (RGEN) Stock Up 4.3% and Still Undervalued -- GF S - GuruFocus
Repligen Earnings: Excellent Profit Margins, China Recovery Underway - Morningstar
Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP - MarketBeat
Vanguard Capital Management reports 5% Repligen (RGEN) stake in Schedule 13G - Stock Titan
Repligen Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade - Yahoo Finance
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up - Barchart.com
Canaccord reiterates Hold on Repligen stock, keeps $145 target By Investing.com - Investing.com Nigeria
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Repligen Corp (RGEN) Shares Surge 11.0% -- What GF Score of 87 T - GuruFocus
Repligen Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript - AlphaStreet
Is Repligen Corp (RGEN) Undervalued After Q2 Earnings Beat? EPS - GuruFocus
Repligen raises FY2026 adj EPS guidance to $2.03-$2.09 - scanx.trade
Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance - TradingView
Repligen Q2 2026 revenue rises 12% to $204 million - Quiver Quantitative
Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance - Quiver Quantitative
Repligen: Q2 Earnings Snapshot - Yahoo Finance
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance - Yahoo Finance
Repligen Corp (RGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Repligen Corp (RGEN) Balance Sheet - TradingKey
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen earnings in focus after $1.5B BioLife acquisition By Investing.com - Investing.com South Africa
Repligen Corp (RGEN) Institutional Confidence - TradingKey
RGEN|Repligen Corp|Price:131.960|Chg%:-5.640 - TradingKey
Repligen Corp (RGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
Repligen Corp (RGEN) Cash Flow - TradingKey
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp Azioni (RGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Repligen Corp Azioni (RGEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer |
Aug 20 '26 |
Option Exercise |
141.79 |
5,426 |
769,353 |
59,672 |
| Loeillot Olivier | Chief Executive Officer |
Aug 20 '26 |
Sale |
180.00 |
5,426 |
976,680 |
54,246 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):